Get started
ANAVEX LIFE SCIENCES CORPORATION USD0.001ANAVEX LIFE SCIENCES CORPORATION USD0.001ANAVEX LIFE SCIENCES CORPORATION USD0.001

ANAVEX LIFE SCIENCES CORPORATION USD0.001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0HFR chart


Full chart

0HFR upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪731.79 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.502 USD
Net income (FY)
‪−47.51 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪82.10 M‬
Beta (1Y)
2.22

Employees


Employees (FY)
40
Change (1Y)
+2 +5.26%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.19 M‬ USD

About Anavex Life Sciences Corp.


Sector
Health Technology
Industry
Biotechnology
CEO
Christopher U. Missling
Website
anavex.com
Headquarters
New York
Founded
2004
FIGI
BBG00JWMZ7R1
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0HFR news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0HFR is 8.706 USD — it has decreased by −2.95% in the past 24 hours. Watch ANAVEX LIFE SCIENCES CORPORATION USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ANAVEX LIFE SCIENCES CORPORATION USD0.001 stocks are traded under the ticker 0HFR.
0HFR stock has risen by 1.22% compared to the previous week, the month change is a 5.13% rise, over the last year ANAVEX LIFE SCIENCES CORPORATION USD0.001 has showed a −6.70% decrease.
We've gathered analysts' opinions on ANAVEX LIFE SCIENCES CORPORATION USD0.001 future price: according to them, 0HFR price has a max estimate of 46.00 USD and a min estimate of 15.00 USD. Watch 0HFR chart and read a more detailed ANAVEX LIFE SCIENCES CORPORATION USD0.001 stock forecast: see what analysts think of ANAVEX LIFE SCIENCES CORPORATION USD0.001 and suggest that you do with its stocks.
0HFR reached its all-time high on Jun 28, 2021 with the price of 32.600 USD, and its all-time low was 2.080 USD and was reached on May 9, 2018. View more price dynamics on 0HFR chart.
See other stocks reaching their highest and lowest prices.
0HFR stock is 7.67% volatile and has beta coefficient of 2.22. Track ANAVEX LIFE SCIENCES CORPORATION USD0.001 stock price on the chart and check out the list of the most volatile stocks — is ANAVEX LIFE SCIENCES CORPORATION USD0.001 there?
Today ANAVEX LIFE SCIENCES CORPORATION USD0.001 has the market capitalization of ‪731.78 M‬, it has increased by 9.55% over the last week.
Yes, you can track ANAVEX LIFE SCIENCES CORPORATION USD0.001 financials in yearly and quarterly reports right on TradingView.
ANAVEX LIFE SCIENCES CORPORATION USD0.001 is going to release the next earnings report on Dec 23, 2024. Keep track of upcoming events with our Earnings Calendar.
0HFR earnings for the last quarter are −0.14 USD per share, whereas the estimation was −0.16 USD resulting in a 12.50% surprise. The estimated earnings for the next quarter are −0.16 USD per share. See more details about ANAVEX LIFE SCIENCES CORPORATION USD0.001 earnings.
ANAVEX LIFE SCIENCES CORPORATION USD0.001 revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
0HFR net income for the last quarter is ‪−12.21 M‬ USD, while the quarter before that showed ‪−10.55 M‬ USD of net income which accounts for −15.82% change. Track more ANAVEX LIFE SCIENCES CORPORATION USD0.001 financial stats to get the full picture.
No, 0HFR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 40.00 employees. See our rating of the largest employees — is ANAVEX LIFE SCIENCES CORPORATION USD0.001 on this list?
Like other stocks, 0HFR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ANAVEX LIFE SCIENCES CORPORATION USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ANAVEX LIFE SCIENCES CORPORATION USD0.001 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ANAVEX LIFE SCIENCES CORPORATION USD0.001 stock shows the buy signal. See more of ANAVEX LIFE SCIENCES CORPORATION USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.